Eton Pharmaceuticals Inc
ETON
View Detailed Chart
23.240USD
-0.210-0.90%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
379.24MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.90%
5 Days
+4.12%
1 Month
+36.79%
6 Months
+9.26%
Year to Date
+37.43%
1 Year
+78.49%
View Detailed Chart
TradingKey Stock Score of Eton Pharmaceuticals Inc
Currency: USD Updated: 2026-03-27Key Insights
Eton Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Eton Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Eton Pharmaceuticals Inc Highlights
StrengthsRisks
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 152.67% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.95M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 79.95M.
Undervalued
The company’s latest PE is -135.91, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.82M shares, decreasing 0.00% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 6.29K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.64.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
37.667
Target Price
+60.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Eton Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Eton Pharmaceuticals Inc Info
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Ticker SymbolETON
CompanyEton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
Websitehttps://etonpharma.com/
Related Instruments
-2.10%
-1.92%
+0.49%
+2.48%
+0.58%
-0.88%
-0.98%
-1.24%
-0.51%
-1.96%
-1.02%
+0.34%
-0.19%
-1.55%
-4.56%
0.00%
-0.55%
-2.51%
-2.86%
-0.83%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
65198.040
-1386.010 (-2.08%)
275.340
+1.990 (+0.73%)
1948.470
-51.530 (-2.58%)
361.830
-10.280 (-2.76%)
4489.360
-3.160 (-0.07%)
101.791
+1.182 (+1.18%)
1.149
-0.002 (-0.17%)
160.396
+0.144 (+0.09%)
